About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, January 22nd, 2016

The QualityStocks
Daily Stock List


Propanc Health Group Corp. (PPCH)

Ceocast News, PennyPro, PennyStocks24, Greenbackers, PennyStockRumors.net, PricelessPennyStocks and Top Stock Picks reported on Propanc Health Group Corp. (PPCH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Propanc Health Group Corp. is an emerging healthcare company centering on the development of new and proprietary treatments for cancer patients, especially those suffering from pancreatic and colorectal cancer. The Company has developed - together with its scientific and oncology consultants - a rational, composite formulation of anti-cancer compounds, which enable and support an array of cancer treatment options. Propanc Health Group is a development stage healthcare company.

Propanc’s leading products are variations upon its novel formulation and involve or employ proenzymes. These are inactive precursors of enzymes. The Company’s intention in the near term is to target patients with limited remaining therapeutic options for the treatment of solid tumors. This includes colorectal or pancreatic tumors. In the future, its plan is to develop its lead product to treat early stage cancer, pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic screening.  

In 2014, Propanc announced that it made substantial progress in association with its ongoing efforts to secure acceptance and approval of patent applications filed worldwide. The Company’s leading products are PRP and PRP-DCM. These are novel, patented suppository formulations based on proteolytic proenzymes that are inactive precursors of enzymes.

PRP is a novel, patented, once daily suppository formulation of proteolytic proenzymes. Concerning PRP-DCM, work undertaken by Propanc has focused on maximizing the potential of PRP as a drug suitable for long term maintenance. Scientific research has centered on developing a novel combination of anti-cancer agents working in combination with proteolytic proenzymes, which enhance PRP’s anti-cancer effects.

Numerous preclinical activities are underway for Propanc’s lead product, PRP. Animal efficacy studies in several tumor cell lines are underway for PRP with the Company’s research partner, vivoPharm, in Hershey, Pennsylvania. Additionally, it has selected pancreatic cancer as its lead indication for human studies. With the background development history of PRP, its uniqueness as a potential treatment for pancreatic cancer, and the size of the target patient population for pancreatic cancer, Propanc Management will seek Orphan Drug Designation for PRP for this indication in each jurisdiction.

Last week, Propanc Health Group announced it received a further $525,000 tranche from an institutional investor in order to progress its lead product, PRP, towards human trials. To date, Propanc has received roughly $2.4 Million from the Institutional Investor since the Securities Purchase Agreement, Debenture and Warrant (Financing Documents) were executed by both parties on October 28, 2015. The balance of the investment amount of around $1.6 Million will be paid (totaling $4 Million) in the future. This is pending the attainment of certain equity conditions set forth in the Financing Documents, as described in Propanc Health Group’s recent filings.

Propanc Health Group Corp. (PPCH), closed Friday's trading session at $0.0187, down 7.43%, on 7,579,065 volume with 193 trades. The average volume for the last 60 days is 4,377,109 and the stock's 52-week low/high is $0.0021/$0.1338.

El Capitan Precious Metals, Inc. (ECPN)

PennyTrader Publisher and AllPennyStocks reported previously on El Capitan Precious Metals, Inc. (ECPN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is a mining company headquartered in Scottsdale, Arizona. It principally engages in the mining of precious metals and other minerals. The Company primarily holds interest in the El Capitan gold-silver property located close to Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals’ shares trade on the OTCQB.

The Company’s main asset is its wholly-owned subsidiary El Capitan, Ltd., an Arizona corporation. This subsidiary holds the 100 percent equity interest in the El Capitan property. The El Capitan deposit has been known as a potential iron ore resource for a number of decades. The El Capitan deposit is within a north-south-trending belt approximately two miles in width and 10 miles in area, which is underlain by Permian limestone and lesser quartz sandstone.

El Capitan Precious Metals’ main goal is the sale of the El Capitan property. It owns 3,840 acres of mining property in Lincoln County. This includes 80 acres of patented and 3,760 acres of leased property. These include 188 mining claims. The El Capitan property consists of 354 Bureau of Land Management (BLM) lode claims and four patented claims.

Numerous recovery methods have been utilized in extracting ore from the El Capitan property. These methods include the alkali fusion method, silver lead collection, and carbon pre-roast with silver-lead recovery. The El Capitan deposit has a near-surface, pervasive nature. All of this occurs above the regional water table. This provides the potential for a low mining cost and a long life operation.

Today, El Capitan Precious Metals announced that it enhanced its relationship with Logistica US by way of a new agreement under which El Capitan will provide to Logistica concentrated ore to their specifications at the mine site. Logistica will transport, process, and refine the precious metals concentrates to sell to precious metals buyers. The agreement is in addition to and complements the earlier announced agreement for the sale of iron ore for use in construction.

El Capitan Precious Metals, Inc. (ECPN), closed Friday's trading session at $0.0525, up 5.00%, on 212,810 volume with 25 trades. The average volume for the last 60 days is 283,588 and the stock's 52-week low/high is $0.045/$0.155.

OxySure Systems, Inc. (OXYS)

MarketWireStocks, PennyStockLocks.com, ResearchOTC, StockRockandRoll, SECFilings.com News, Stock Commander, PennyStockProphet, Planet Penny Stocks, Buzz Stocks, PennyStocks24, Penny Pick Finders, StockOnion, SecretStockPromo, MicroCapDaily, OTCMagic, and Winston Small Cap reported recently on OxySure Systems, Inc. (OXYS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OxySure Systems, Inc. is an international leader and medical device innovator of life-saving, user-friendly emergency oxygen solutions with its "oxygen from powder" technology. The Company concentrates on the design, manufacture, and distribution of specialty respiratory and medical solutions. It pioneered a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders.

A medical technology company, OxySure Systems is based in Frisco, Texas. Recently, OxySure Systems announced the completion of its name change to OxySure Therapeutics, Inc. The Company's ticker symbol will remain the same - OXYS.

OxySure owns numerous issued patents and patents pending on the aforementioned technology. This technology makes the provision of emergency oxygen safer, more accessible, and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen, which affects the survival, recovery, and safety of individuals in many areas of need.

The proprietary process and methodology is for the emergency/short duration oxygen supply market. With this technology, oxygen is produced on demand and there is no storage of oxygen. Furthermore, there are no compressed tanks, dials, valves, or regulatory maintenance. In addition, there is no hydrostatic testing, no batteries, no required training, and none of the hazards associated with traditional oxygen provision systems.

OxySure’s launch product using this technology is the OxySure Model 615. This is a portable emergency oxygen device for lay person use. Model 615 bridges the gap between the beginning of a medical emergency and the time first responders arrive on the scene. In addition to oxygen products for public/lay responder usage, the Company also markets emergency medical solutions. These include AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products, and pulse oximetry products.

Recently, OxySure launched its OxyTrac™ technology. Via a cloud-based solution, the technology helps quickly locate all emergency response devices on the premises, facilitates availability of extra help via a contact database, and ensures that devices are properly inspected. This is while tracking expiration dates for batteries or other consumables. OxyTrac™ is compatible with a broad variety of emergency response devices.

Last week, OxySure Systems - now named OxySure Therapeutics - announced that Dr. Zachariah P. Zachariah, a former Director of Ivax Corp. (together with its Chairman Dr. Phil Frost) will be joining OxySure's Strategic Advisory Board effective immediately. Ivax is a marketer of a patented asthma inhaler called Easi-Breathe and other branded respiratory drugs. Teva Pharmaceutical Industries acquired Ivax for $7.4 billion.

OxySure Systems, Inc. (OXYS), closed Friday's trading session at $0.1979, up 3.40%, on 20,795 volume with 14 trades. The average volume for the last 60 days is 155,619 and the stock's 52-week low/high is $0.17/$1.12.

OptimizeRx Corp. (OPRX)

Streetwise Reports and Bull in Advantage reported previously on OptimizeRx Corp. (OPRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OptimizeRx Corp. provides innovative consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. The Company does so while providing pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications. The Company’s core product is SampleMD. OptimizeRx has its headquarters in Rochester, Michigan and the Company lists on the OTC Markets Group’s OTCQB.

OptimizeRx’s SampleMD replaces drug samples with electronic trial vouchers and copay coupon savings. These are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the country. These include Allscripts, Quest Diagnostics, Practice Fusion and in excess of 350 other EHRs to reach more than 250,000 healthcare providers.

OptimizeRx’s services include SAMPLEMD® E-Coupons; Patient Education; On-Demand Support; EHR Brand Messaging; New Product Launch/Drug File Integration; and EHR Sales Training. It initially launched its SampleMD e-coupon solution in April 2015 within Practice Fusion's EMR.

The Company promotes patients’ savings and support from the world's largest pharmaceutical companies. These include Pfizer, Lilly, Novartis, AstraZeneca and many others. In addition, OptimizeRx has launched OPTIMZEHR™. This is its consulting and implementation practice to assist pharmaceutical-biotech companies and healthcare provider platforms in determining and executing on mutually beneficial opportunities to jointly assist physicians and patients within their electronic health record (EHR) workflow.

Recently, OptimizeRx announced that it appointed Mr. James Brooks to the new position of Senior Vice President of Business Development, effective January 4, 2016. Mr. David Harrell, OptimizeRx’s Chief Executive Officer, said, "James will champion our EHR business through development of new relationships with other EHR providers and patient platforms. He brings to us numerous relationships within large EHRs that can be leveraged to integrate OptimizeRx savings and support to reach more doctors and patients."

Mr. Brooks has greater than 20 years of experience in sales & marketing. This includes sales force development, sales management, and organizational leadership processes within the Electronic Health Record (EHR) and Healthcare Technology sector.

OptimizeRx Corp. (OPRX), closed Friday's trading session at $1.09, up 3.82%, on 41,861 volume with 27 trades. The average volume for the last 60 days is 41,806 and the stock's 52-week low/high is $0.7601/$1.59.

Cool Technologies, Inc. (WARM)

Today, we are reporting on Cool Technologies, Inc. (WARM), here at the QualityStocks Daily Newsletter.

Cool Technologies, Inc. (previously HPEV, Inc.) is an innovator in motor and generator power improvements, energy efficiency, and heat removal technologies. The Company changed its name to Cool Technologies, Inc. in August of 2015. Fundamentally, Cool Technologies is an intellectual property (IP) and engineering company that employs a license & royalty, strategic alliance and joint venture/profit sharing model. The Company formed to commercialize a single patent: a composite heat pipe. Cool Technologies is based in Tampa, Florida.

Further to its name change, Cool Technologies changed its name to reflect the true nature of its foundation technology and better lend itself to the numerous technology verticals to which the technology can apply. The foundation of the Cool Tech technology is the removal of heat from rotating equipment more cost effectively and efficiently than contemporary technology available.

At present, Cool Technologies is commercializing its patented thermal technology and a mobile generation technology. Moreover, the Company has additional patents-pending for a variety of original equipment manufacturer (OEM) applications of its proprietary heat removal technologies. Markets to be addressed by these technologies include industries such as pumps, fans, compressors, batteries, motors, generators and bearings.

Cool Technologies’ thermal dispersion technology can cool electric motors, generators and alternators, and vehicle components. The Company indicates that the market in which its technology has the greatest short term potential is dry pit submersibles. Its thermal technology allows electric motors and generators to produce more power from the same size package. The Company combines a thermally-enhanced motor with its parallel power platform. This is to deliver an electric load assist (or ELA) to any internal combustion engine.

The proprietary technology important to Cool Technologies’ parallel power platform can also be used to power an on-board generator from a vehicle’s internal combustion engine. The generator can subsequently provide up to 250 kilowatts of power. Cool Technologies has expertise in thermal dispersion technologies and their application to an assortment of product platforms.

Yesterday, Cool Technologies announced the test results of its dry-pit submersible motor, verified and validated to increase power output by 400 percent over its leading competitors. Based on a diameter-to-diameter comparison (a standard measurement of size in the motor manufacturing industry) with an international leader in power technologies, ABB, and its Baldor-Reliance 250TY dry pit submersible motor for continuous usage in air, the Cool Technologies' motor registered 40 horsepower versus the 10 horsepower output by the Baldor-Reliance motor.

Cool Technologies, Inc. (WARM), closed Friday's trading session at $0.2095, up 10.26%, on 43,800 volume with 17 trades. The average volume for the last 60 days is 59,964 and the stock's 52-week low/high is $0.1003/$0.75.


The QualityStocks
Company Corner


Lingo Media Corp. (LMDCF)

The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.5284, up 16.80%, on 4,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 8,837, and its 52-week low/high is $0.0862/$0.6745.

Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.

The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.

Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.

Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer

Lingo Media Corp. Company Blog

Lingo Media Corp. News:

Lingo Media Corp. (LMDCF) (LM.V) Continues to Generate Strong Profits with Q3 Net Income of $631,730

Lingo Media to Present at the LD Micro Main Event

Lingo Media to Present at the Small-Cap Conference on November 10th

Alternet Systems, Inc. (ALYI)

The QualityStocks Daily Newsletter would like to spotlight Alternet Systems, Inc. (ALYI). Today, Alternet Systems, Inc. closed trading at $0.015, up 25.00%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 100,829, and its 52-week low/high is $0.0055/$0.045.

Alternet Systems, Inc. (ALYI) invests in and partners with companies that are creating the future of money in the high growth, emerging technology fields of digital commerce, multichannel payments, and predictive analytics.

Vision: Be the leading digital commerce, multichannel payments, predictive analytics solutions provider into global markets

Mission: To provide innovative solutions that facilitates and expedites commerce, enriching our partners and their customers' experience, and improving efficiency. Recognizing that the world is becoming increasingly dependent on technological conveniences, Alternet Systems aims to provide its customers with the tools to prepare themselves for a new era of digital commerce and payments, financial services and consumer information, and, most importantly, a new era of how to live.

Since 2010, Alternet has maintained a progressive focus on the high-growth, mobile value-added service industries of mobile financial services and mobile security. In 2014, the company expanded its scope of expertise to include in its investment verticals the exciting digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, telecommunications and financial industry.

With strategic investments in these three key, high-growth markets, Alternet is accelerating the future of money and its role in the global demand for these services. The company is guided by a team of executives specializing in entrepreneurial endeavors, innovation, corporate strategy, financial and executive management of multi-national organizations, and a vast network of industry resources.

As Alternet embarks on this new path, the company will be led by a management team and board of directors with over a century's worth of combined experience in the fields of investing, technology, and financing, and the consensus knowledge of where to invest and when in start-up and early-stage companies. Disclaimer

Alternet Systems, Inc. Company Blog

Alternet Systems, Inc. News:

Alternet Systems (ALYI) CEO Featured in Exclusive QualityStocks Interview

Alternet Payment Solutions Offers Disruptive Omni-Channel Payment Processing Technology in the U.S.

Alternet Systems Appoints Fabio Alvino as CEO of Alternet Payment Solutions

Oakridge Global Energy Solutions, Inc. (OGES)

The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.569, up 7.36%, on 3,685 vlume with 6 trades. The stock’s average daily volume over the past 60 days is 19,088, and its 52-week low/high is $0.20/$2.40.

Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.

Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.

The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.

Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer

Oakridge Global Energy Solutions, Inc. Company Blog

Oakridge Global Energy Solutions, Inc. News:

Oakridge Announces New Corporate Image, Branding and Media Communications Tools as it Enters Full-Scale Production for 2016

Oakridge Providing Batteries for Unmanned Maritime Vessels

Oakridge Sells Interest in Leclanche S.A., Releasing Funding for Corporate Growth

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.027, up 8.00%, on 629,685 volume with 24 trades. The stock’s average daily volume over the past 60 days is 1,245,664 and its 52-week low/high is $0.0035/$0.40.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

U.S. Securities and Exchange Commission Approves Dominovas Energy's S-1 Registration

Dominovas Energy Signs Financing Agreement With GHS Capital

Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.0285, up 3.26%, on 194,714 volume with 10 trades. The stock’s average daily volume over the past 60 days is 325,056, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma CEO, Rik J Deitsch, Has Published a Letter to Shareholders Outlining the Current Efforts and the Future Goals of the Company

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Investment U




Money Morning

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251